Is eZH2 expression a prognostic factor in childhood intracranial ependymoma : a Canadian Pediatric Brain Tumor Consortium study?
EZH2 is a novel, independent marker of a poor prognosis in patients with ependymoma, especially in those who have tumors located in the posterior fossa. EZH2, pAKT, and P16 are potential therapeutic targets, particularly for patients who have tumors in which standard gross total resection plus fractionated radiotherapy is not feasible.
Findings suggest that participants' criminal histories primarily reflect "symptoms" of homelessness rather than threats to public safety. Further, the extent of participants' criminal histories was not associated with subsequent jail time or housing attrition. Although causation cannot be implied, these findings show that the amount of time spent in project-based HF is associated with decreased jail time for up to two years following initial HF exposure.